Market Mover: RAPT (RAPT) Up at Midday August 5

Equities Staff  |

Shares of RAPT Therapeutics Inc (NASDAQ: RAPT) rose 16.00% Friday.

As of 11:53:27 est, RAPT is currently sitting at $21.51 and has climbed $2.98 so far today.

RAPT has moved 5.77% over the last 30 days and has a YTD change of 44.62% based on the prior day’s close.

The company is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on RAPT visit the company profile.

About RAPT Therapeutics Inc

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

To get more information on RAPT Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: RAPT Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content